

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 October 2011 (27.10.2011)

(10) International Publication Number  
**WO 2011/132167 A1**

PCT

(51) International Patent Classification:

*A61K 9/00* (2006.01) *A61K 9/50* (2006.01)  
*A61K 9/16* (2006.01)

(21) International Application Number:

PCT/IB2011/051736

(22) International Filing Date:

20 April 2011 (20.04.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1053034 21 April 2010 (21.04.2010) FR

(71) Applicant (for all designated States except US):  
**SANOFI-AVENTIS** [FR/FR]; 174 avenue de France,  
F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LESOT, Axelle**  
[FR/FR]; c/o sanofi-aventis, Patent Department, 174 avenue de France, F-75013 Paris (FR). **LEYDET, Damia**  
[FR/FR]; c/o sanofi-aventis, Patent Department, 174 avenue de France, F-75013 Paris (FR). **MOUSSEL, Arnaud**  
[FR/FR]; c/o sanofi-aventis, Patent Department, 174 avenue de France, F-75013 Paris (FR).

(74) Agent: **CARION-TARAVELLA, Brigitte**; c/o sanofi-aventis, Patent Department, 174 avenue de France, F-75013 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— of inventorship (Rule 4.17(iv))

**Published:**

— with international search report (Art. 21(3))

(54) Title: METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS INTENDED FOR ORAL ADMINISTRATION COMPRISING ONE OR MORE ACTIVE INGREDIENTS AND THE COMPOSITIONS COMPRISING SAME

(57) Abstract: The present invention relates to a method for "hot melt coating" of pharmaceutical active ingredients characterized by organoleptic or physicochemical properties that it is desirable to mask. The invention also relates to the resulting medicinal active ingredients with masked organoleptic or physicochemical properties and the compositions comprising same.



WO 2011/132167 A1

**Method for preparing pharmaceutical compositions intended for oral  
administration comprising one or more active ingredients and the compositions  
comprising same**

5

**FIELD OF THE INVENTION**

The present invention relates to a method for hot melt coating of pharmaceutical active ingredients. These active ingredients are characterized by organoleptic or physicochemical properties that it is desirable to mask. Thus, the pharmaceutical active ingredients may have unacceptable organoleptic properties (taste, odour, colour, appearance), in particular their strong bitterness. These pharmaceutical active ingredients may be sensitive to moisture and/or to temperature. This method therefore allows effective masking of unsatisfactory organoleptic and/or physicochemical properties of pharmaceutical active ingredients, without however slowing down the dissolution of said active ingredient. The invention also relates to the resulting medicinal active ingredients with masked organoleptic or physicochemical properties and to the compositions comprising same.

**PRIOR ART AND TECHNICAL PROBLEM**

In the context of the masking of the taste of active ingredients which have an unacceptable taste, many tests, using conventional technologies, have been carried out: granulation, coating in a fluidized air bed, etc. The excipients tested were composed of polymers: mainly cellulose derivatives (HPC, HPMC, EC) and derivatives of methacrylic acid (Eudragit range) and of polyvinyl acetate. These tests often came up against insufficient taste masking.

Moreover, more innovative technologies have also been used, such as microencapsulation by means of a supercritical CO<sub>2</sub>-phase process or by means of a simple or complex coacervation method. The same masking polymers, mentioned above, are found, as are other less conventional excipients such as chitosan, alginates or gelatin. The major drawbacks encountered in these technologies are implementation and industrial feasibility.

In the same approach, spray-drying and spray-cooling processes have been tested.

The latter "spray-cooling" technology described in **WO/2004/058137** consists in melting a fatty matrix and incorporating the active ingredient therein. The latter is either dissolved or dispersed in the fatty phase, composed of fatty acids, of a mixture or of esters of fatty acids, of fatty alcohol or of waxes.

The molten mixture is then conveyed, via a peristaltic pump, to a two-fluid nozzle where it is atomized into more or less fine droplets (according to the parameters applied). The droplets are finally cooled by a stream of cold air within the atomization chamber and converted into solid granules containing the active ingredient dispersed throughout the  
5 fatty matrix.

Although this spray-cooling method makes it possible to obtain pharmaceutical compositions with correct taste masking while at the same time providing dissolution of the active ingredient which is not slowed down in an acidic medium, there remains, however, an unsolved problem of physical heat-stability of the product obtained.  
10 Likewise, this method remains incompatible with active ingredients which are heat-sensitive by nature.

Furthermore, in the context of this "spray-cooling" method, the concentration of the active ingredient of the composition is limited by the viscosity of the solution or suspension to be sprayed, which greatly reduces the active ingredient content of the  
15 composition of the coated granule. It is possible to obtain only compositions with low doses of active ingredient, i.e. compositions comprising an amount of active ingredient not exceeding 30% by weight in the composition of the coated granule.

Moreover, the use of the hot melt coating method has been described in **WO02/07706**. That document describes the use of this technology for coating heat-  
20 sensitive active ingredients in the form of solid particles which have not been pregranulated. The amounts of coating targeted are low and do not make it possible to satisfactorily mask the taste of very unpleasant active ingredients.

Likewise, **WO9718798** describes prompt-release pharmaceutical compositions suitable in particular for oral administration, comprising microcrystals or microgranules of  
25 active agents, a lipid coating obtained by means of a hot melt coating method and a vehicle comprising excipients. The concentration of fatty matrix of the coating is between 1% and 25%, preferably between 5% and 20%. That document specifies that, in order to mask the unpleasant taste of an active ingredient while at the same time allowing satisfactory release of the active agent, it is necessary to work with sufficiently low levels  
30 of fatty matrix. This condition is necessary so as not to modify the dimensions of the coating layer, which would then influence the release of the active ingredient. However, the amounts of lipid coating proposed are low and do not make it possible to satisfactorily mask the taste of very unpleasant active ingredients.

As a result, the use of the hot melt coating method described in these documents is  
35 not suitable for obtaining sufficiently effective masking of the taste and of the odour of an

active ingredient characterized by a strong bitterness and a strong odour, in particular masking sufficient to allow ingestion of the medicament by a child.

The applicant has now found a novel improved method which makes it possible to solve these drawbacks.

5

### **SUMMARY OF THE INVENTION**

The objective of the invention is to propose a novel method which solves at least the drawbacks mentioned above.

10 The problem solved by this method of production which comprises formulation using fatty matrices, is that of the masking of the taste of certain active ingredients while at the same time obtaining a relatively rapid release of the active ingredient in vitro (for example a minimum release of 70% of active ingredient in 60 minutes).

Furthermore, the maximum concentration of active ingredient that can be used in this method is not limited; the resulting product can contain a high dose, i.e. it is possible  
15 to obtain compositions that can comprise an amount of active ingredient exceeding 30% by weight in the composition of the coated granule. This makes it possible to notably reduce the doses of products to be administered to the patient, in particular to young children or to the elderly.

According to an additional advantage, this method makes it possible to obtain a  
20 high dosage of the active ingredient even when the latter is heat-sensitive. Furthermore, it is observed that the final products obtained exhibit satisfactory physical stability, in particular under storage conditions subjected to heat (at 30°C/65% RH).

Moreover and surprisingly, this method makes it possible to provide certain sensitive active ingredients with protection against moisture. This is because the  
25 presence of this lipid coating appears to make it possible to establish a barrier against moisture.

According to another additional advantage, this method makes it possible, by virtue of the quality of the coating, to inhibit the anaesthetic and unpleasant effect of certain active molecules generally felt in the oral cavity.

30 The invention therefore proposes a method for preparing a composition of medicinal active ingredient comprising (a) a granular centre consisting of grains of active ingredient, agglomerated in the presence of binder, and (b) a layer of coating of said granular centre consisting of fatty matrix, in which composition:

- the active ingredient represents a minimum of 10%, preferably 20% or else  
35 30% by weight, relative to the weight of the composition of the coated granule; the active ingredient represents a maximum of 48%, preferably a maximum of 40%, the

active ingredient preferably represents from 20% to less than 40%, relative to the weight of the composition of the coated granule, more preferentially the active ingredient represents from 30% to 40%, relative to the weight of the composition of the coated granule;

5       • the fatty matrix represents more than 50% and up to 85% by weight of the composition of the coated granule, preferably from 51% to 65%, the fatty matrix optionally comprising an adjuvant, preferably chosen from hydrophilic agents, surfactants or mixtures thereof, and the latter representing less than 10%, preferably from 1% to 3% by weight, relative to the weight of the composition of the coated granule;

10       • the binder, preferably a hydrophilic agent chosen from hydrophilic polymers or hot-melt agents, represents from 0.2% to 18% by weight, relative to the weight of the composition of the coated granule, preferably the binder represents less than 18% by weight for a hot-melt agent or else preferably the binder represents less than 10% by weight for a hydrophilic polymer;

15       • the diluent, if necessary, as filler, represents a content of 0 to 39%, relative to the weight of the composition of the coated granule;

      • the lubricant, if necessary, as flow agent, represents a content of 0 to 1.8%, relative to the weight of the composition of the coated granule;

20       the method comprising the steps of:

      E1) preparing the granular centre by spraying an aqueous solution comprising the binder or by spraying the binder in the molten state onto the active ingredient alone or as a mixture with a diluent and/or a lubricant;

25       E2) coating by spraying, onto the granules, said fatty matrix pre-melted in a melting kettle at a temperature approximately 10 to 20°C above its melting point;

      E3) cooling the composition obtained.

      According to one preferred embodiment, the method makes it possible to prepare a composition in which:

30       • the active ingredient represents a minimum of 10% and a maximum of 48%, preferably from 20% to less than 40% by weight of the composition of the coated granule, and

      • the fatty matrix comprising an adjuvant represents more than 50% and up to 85% by weight of the composition of the coated granule.

35       According to another preferred embodiment, the method makes it possible to prepare a composition in which:

- the active ingredient represents from 30% to 40%, relative to the weight of the composition of the coated granule, and
- the fatty matrix represents from 51% up to 65% by weight of the composition of the coated granule.

5 Preferably, the granular centre of active ingredient is coated only with a single layer of coating.

Preferably, the size of the coated granules obtained at the end of step E3) is less than 500  $\mu\text{m}$ , preferably less than 355  $\mu\text{m}$ , preferably ranging from 100 to 300  $\mu\text{m}$ .

Preferably, the particle size of the final product obtained at the end of step E3) is  
10 distributed according to the following range:

- less than 15% by weight of the coated granules are greater than 500  $\mu\text{m}$ ;
- more than 80% by weight, preferably more than 90% by weight, of the coated granules are between 355 and 90  $\mu\text{m}$ ; and
- less than 20% by weight, preferably less than 5% by weight, of the coated  
15 granules are less than 90  $\mu\text{m}$ .

Preferably, the aqueous solution used in step E1 comprises, as binder, a hydrophilic polymer preferably chosen from the group of cellulosic derivatives (hydroxypropylcellulose), povidone (polyvinylpyrrolidone), sucrose, gums, starches, gelatin and macrogols (polyethylene glycols), which represents approximately from 15%  
20 to 45%, preferably 20% to 40% by weight of said aqueous solution.

Preferably, the binder used in step E1 for the granulation is a hot-melt agent chosen from macrogols (PEGs), sucroesters or else poloxamers, and represents approximately from 0.2% to 20%, preferably from 1% to 15% by weight, relative to the amount of active ingredient to be granulated in step E1).

25 According to one particular embodiment, the aqueous solution used in step E1 is sprayed onto the active ingredient mixed with a diluent (filler). The diluents used in granulation for increasing the load to be granulated are preferably chosen from polyols, celluloses, sugars, lactoses, starches, kaolin, calcium phosphates, calcium carbonates or magnesium carbonates, or derivatives thereof. This diluent represents approximately  
30 from 0 to 39%, preferably 5% to 15% by weight of the composition of the coated granule. Said diluent may optionally act as a permeabilizing agent thus facilitating dissolution of the active ingredient.

Preferably, the fatty matrix consists of saturated fatty acids with long C14 to C22, preferably C16 to C18, carbon-based chains, pure or as mixtures, and/or their  
35 corresponding fatty alcohols.

Preferably, the fatty matrix consists of stearic acid, palmitic acid, myristic acid, pure or as mixtures, and/or their corresponding fatty alcohols. More preferentially, the fatty matrix consists only of stearic acid, which is a C18 saturated fatty acid.

Preferably, the adjuvant as a mixture with the fatty matrix is chosen from the group of surfactants (phospholipid, polysorbate, lauryl sulphate), hydrophilic excipients such as sucrose, polyols, cellulose, lactose, silica, dicalcium phosphate, carbonates, starch, macrogols and agents which are soluble at acidic pH (methacrylic derivatives), pure or as mixtures. Preferably, the adjuvant used is a glycerolipid, in particular a phospholipid. More preferentially, this phospholipid is a lecithin (phosphatidylcholine), preferably soybean lecithin.

Said fatty matrix coating the granular centre preferably consists of stearic acid and the adjuvant as a mixture with the fatty matrix is soybean lecithin.

Preferably, the percentage by weight of the adjuvant added to the fat in step E2 is less than 10% by weight, preferably less than 5% by weight, preferably ranging from 1% to 3% by weight, relative to the weight of the composition of the coated granule.

Preferably, the percentage by weight of the binder constituting the coating of the granule obtained in step E1 represents from 1% to 5% by weight, relative to the weight of the composition of the coated granule, for a hydrophilic polymer and from 0.2% to 18% for a hot-melt agent.

Preferably, the active ingredient is chosen from the group consisting of antibiotics such as cephalosporins and macrolides, advantageously chosen from: pristinamycin, cefpodoxime, roxithromycin, spiramycin, rovamycin and levofloxacin, or the group consisting of corticoids such as prednisolone or methylprednisolone, or else the group consisting of NSAIDs such as tiaprofenic acid, ketoprofen, ketoprofen lysinate or ibuprofen, or the group consisting of analgesics such as paracetamol, or else the group consisting of zopiclone, riluzole, zolpidem, clobazam, thiocolchicoside, drotaverine hydrochloride or base, amodiaquine hydrochloride, diltiazem, levocetirizin, mizolastine, dronedarone, celivarone, dramamine, ramipril, irbesartan, clopidogrel, leflunomide, nicorandil, lysine acetyl salicylate, magnesium citrate, levothyroxine, sodium valproate, rifampicin, artesunate and omeprazole.

Preferably, the method is followed by a step E4 of formulating the coated granules obtained in step E3 with excipients such as diluents, fillers, viscosity modifiers, disintegrating agents, effervescent agents, colourants, sweeteners, salivating agents, flavourings, buffers and sequestering agents, flow agents and lubricants for producing an oral form in the form of granules for sachets, granules for oral suspension, or granules for conventional tablets or for orodispersible tablets.

According to another subject, the invention relates to a composition of medicinal active ingredient comprising (a) a granular centre consisting of grains of active ingredient agglomerated in the presence of binder and, optionally, of diluent or of lubricant, and (b) a layer of coating of said granular centre consisting of a fatty matrix, in which composition:

- 5       • the active ingredient represents a minimum of 10%, preferably 20% or else 30% by weight, relative to the weight of the composition of the coated granule; the active ingredient represents a maximum of 48%, preferably a maximum of 40%, the active ingredient preferably represents from 20% to less than 40%, relative to the weight of the composition of the coated granule, more preferentially the active  
10       ingredient represents from 30% to 40%, relative to the weight of the composition of the coated granule;
- the fatty matrix represents more than 50% and up to 85% by weight of the composition of the coated granule, preferably from 51% to 65%, the fatty matrix optionally comprising an adjuvant, preferably chosen from hydrophilic agents,  
15       surfactants or mixtures thereof, and the latter representing less than 10%, preferably from 1% to 3% by weight, relative to the weight of the composition of the coated granule;
- the binder, preferably a hydrophilic agent chosen from hydrophilic polymers or hot-melt agents, represents from 0.2% to 18% by weight, relative to the weight of the  
20       composition of the coated granule, preferably the binder represents less than 18% by weight for a hot-melt agent or else preferably the binder represents less than 10% by weight for a hydrophilic polymer;
- the diluent, if necessary, as filler, represents a content of 0 to 39%, relative to the weight of the composition of the coated granule;
- 25       • the lubricant, if necessary, as flow agent, represents a content of 0 to 1.8%, relative to the weight of the composition of the coated granule.

Preferably, in the composition of medicinal active ingredient according to the invention, said fatty matrix consists of saturated fatty acids with long C14 to C22, preferably C16 to C18, carbon-based chains, pure or as mixtures, and/or their  
30       corresponding fatty alcohols, and the binder is chosen from hydrophilic polymers. More preferentially, the fatty matrix consists only of stearic acid, which is a C18 saturated fatty acid.

Preferably, said fatty matrix comprises an adjuvant chosen from the group of surfactants (phospholipid, polysorbate, lauryl sulphate), hydrophilic excipients such as  
35       sucrose, polyols, cellulose, lactose, silica, dicalcium phosphate, carbonates, starch, macrogols and agents which are soluble at acidic pH (methacrylic derivatives), pure or as

mixtures, preferably phospholipids. Preferably, the adjuvant used is a glycerolipid, in particular a phospholipid. More preferentially, this phospholipid is a lecithin (phosphatidylcholine), preferably soybean lecithin.

Preferably, said fatty matrix coating the granular centre consists of stearic acid and  
5 the adjuvant as a mixture with the fatty matrix is soybean lecithin.

Preferably, the adjuvant is a surfactant which represents less than 10% by weight, preferably less than 5% by weight, preferably from 1% to 3% by weight, relative to the weight of the composition of the coated granule.

Preferably, the active ingredient is chosen from the group consisting of antibiotics  
10 such as cephalosporins and macrolides, advantageously chosen from: pristinamycin, cefpodoxime, roxithromycin, spiramycin, rovamycin and levofloxacin, or the group consisting of corticoids such as prednisolone or methylprednisolone, or else the group consisting of NSAIDs such as tiaprofenic acid, ketoprofen, ketoprofen lysinate or ibuprofen, or the group consisting of analgesics such as paracetamol, or else the group  
15 consisting of zopiclone, riluzole, zolpidem, clobazam, thiocolchicoside, drotaverine hydrochloride or base, amodiaquine hydrochloride, diltiazem, levocetirizin, mizolastine, dronedarone, celivarone, dramamine, ramipril, irbesartan, clopidogrel, leflunomide, nicorandil, lysine acetyl salicylate, magnesium citrate, levothyroxine, sodium valproate, rifampicin, artesunate and omeprazole.

20 Preferably, the amount of active ingredient represents more than 10% by weight and ranges up to 48% by weight, relative to the weight of the composition of the coated granule.

Preferably, the amount of active ingredient represents more than 10% by weight of the composition of the coated granule and the fatty matrix comprises an adjuvant.

25 Preferably, the amount of active ingredient represents from 20% to less than 40% by weight of the composition of the coated granule.

Preferably, the composition of the active ingredient according to the invention is obtained by means of the method as described above.

According to another subject, the invention relates to a pharmaceutical composition  
30 comprising the composition of medicinal active ingredient as described above or else which can be prepared according to the method described above.

According to another subject, the invention relates to a sachet for an oral suspension comprising the composition of active ingredient as defined above in the presence of an excipient chosen from diluents, viscosity modifiers, disintegrating agents, sequestering agents, buffers, preservatives, lubricants, wetting agents, effervescent  
35 agents, colourants, sweeteners, salivating agents or flavourings.

According to another subject, the invention relates to tablets to be chewed, swallowed or sucked, or orodispersible or water-dispersible tablets with a masked taste, comprising the composition of active ingredient as defined above in the presence of an excipient chosen from diluents, binders, lubricants, salivating agents, anaesthetic agents, wetting agents, preservatives, flow agents, disintegrating agents, colourants, sweeteners or flavourings.

According to another subject, the invention relates to a powder to be swallowed, with masked taste, comprising the composition of active ingredient as defined above in the presence of an excipient chosen from diluents, salivating agents, effervescent agents, flow agents, preservatives, colourants, sweeteners or flavourings.

According to another subject, the invention relates to the use of a composition of medicinal active ingredient as defined above or prepared according to the method described above, for preparing pharmaceutical compositions in the form of sachets for an oral suspension, powders to be swallowed, tablets to be chewed, tablets to be swallowed, tablets to be sucked, orodispersible tablets or water-dispersible tablets, and having a masked taste.

**DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION****Method for preparing the composition of medicinal active ingredient****1) Granulation step**

5 In a first step of the method, an aqueous wetting solution comprising a binder of hydrophilic polymer type is sprayed onto the active ingredient in the crude state or onto an active ingredient/diluent (filler) mixture or onto an active ingredient/lubricant mixture or an active ingredient/diluent/lubricant mixture.

Preferably, the aqueous solution contains approximately 10% to 45% by weight, preferably 15% to 40% by weight, of binder of hydrophilic polymer type in the aqueous solution.

The parameters used for this granulation step are suitable for the properties of the active ingredient and for the equipment used.

15 The aqueous wetting solution used can be replaced, when moisture-sensitive active ingredients are used, with a hot-melt binder (of macrogol type).

This step makes it possible to obtain an active ingredient which is finely granulated by homogenization and recentring of the particle size distribution of the active ingredient, with the aim of improving the quality of the second, coating step.

20 According to one variant, it is also possible to carry out a calibration of the granular active ingredient obtained in the step above, in order to select the granules having a diameter of less than 500  $\mu\text{m}$ .

**2) Hot-melt coating step**

25 In a second step, the active ingredient in the granular state is preferably fluidized in a fluidized air bed.

The fatty matrix is brought to melting, with stirring, in a melting kettle at a temperature of approximately 10 to 20°C above its melting point.

30 The melting points of the fatty substances used are in the region of from 50 to 80°C, preferentially from 55 to 65°C or else preferably around 60°C. This melting range was preferably chosen, firstly, for reasons of physical stability of the composition thus formulated and, secondly, in order to have, in the end, as prompt a release of active ingredient as possible.

35 According to one preferred embodiment, an adjuvant (surfactant or hydrophilic excipient) is added to the melted fatty matrix with, optionally, a preservative. This adjuvant makes it possible to promote the obtaining of a prompt release profile of the composition.

The molten mixture is then sprayed onto the active ingredient in order to produce a coating by the "hot-melt coating" method. The parameters applied during the coating method are summarized below.

The coating method can be carried out in a fluidized air bed apparatus. The nozzles  
5 are fed, on the one hand, with the molten mixture which circulates via a pump in an entirely thermally-insulated and completed circuit, and secondly, with hot compressed air fed via an air heater.

The main operating parameters applied, which are suitable for the equipment used and the batch size used, are the following:

- 10       - T° of the fatty substance melted: from 70 to 95°C, according to the properties and characteristics of the fatty matrix;
- T° compressed air for spraying: from 80 to 120°C;
- Compressed air pressure: from 0.5 to 1.5 bar;
- T° of the feed circuits: between 80 and 100°C;
- 15       - Liquid flow rate: from 5 to 30 g/min;
- Air flow rate: this is usually adjusted according to the size of the equipment. For an apparatus with a working capacity of 3 kg, an air flow rate of 50 to 160 m<sup>3</sup>/h is generally used, according to the equipment filling load;
- T° air inlet: from 25 to 50°C, according to the properties of the fatty matrix
- 20       used.

At the end of these steps and after cooling, a composition of medicinal active ingredient comprising a granular centre consisting of grains of active ingredient agglomerated in the presence of binder, and a layer of coating of said granular centre consisting of fatty matrix, is obtained.

25       Preferably, the granular centre of active ingredient is coated only with a single layer of coating.

### **Description of the composition of medicinal active ingredient**

#### **1. Active ingredient**

30       The invention relates to any type of active ingredient in the form of solid particles intended to be coated in order to mask their unsatisfactory organoleptic or physicochemical properties.

The active ingredient used in the invention in particular has unpleasant organoleptic properties (taste, odour, appearance), an unacceptable taste and/or an unacceptable  
35       odour, or else it can have an anaesthetic, hot, irritant or astringent effect when it passes

through the oral cavity. In addition, the active ingredient used in the invention may also be heat-sensitive or else moisture-unstable.

It is preferably chosen from the group consisting of antibiotics such as cephalosporins and macrolides, advantageously chosen from: pristinamycin, cefpodoxime, roxithromycin, spiramycin, rovamycin and levofloxacin, or the group consisting of corticoids such as prednisolone or methylprednisolone, or else the group consisting of NSAIDs such as tiaprofenic acid, ketoprofen, ketoprofen lysinate or ibuprofen, or the group consisting of analgesics such as paracetamol, or else the group consisting of zopiclone, riluzole, zolpidem, clobazam, thiocolchicoside, drotaverine hydrochloride or base, amodiaquine hydrochloride, diltiazem, levocetirizin, mizolastine, dronedarone, celivarone, dramamine, ramipril, irbesartan and clopidogrel.

Among the moisture-sensitive active ingredients, mention may be made of: leflunomide, nicorandil, lysine acetyl salicylate, ramipril, magnesium citrate, levothyroxine, sodium valproate, rifampicin, artesunate, clopidogrel and omeprazole.

Amisulpride is excluded from the list of active ingredients used in the invention.

According to one preferred embodiment, the active ingredient used in the invention is chosen from the group consisting of drotaverine hydrochloride or base, clobazam, paracetamol, riluzole, ketoprofen, ketoprofen lysinate, clopidogrel, irbesartan, zopiclone, zolpidem and pristinamycin.

## **2. Active ingredient granulating agents**

The granulating agents used in the first step of the method are binders preferably chosen from hydrophilic agents. They are used in a proportion of from 0.2% to 18% by weight, relative to the weight of the composition of the coated granule.

These hydrophilic agents are particularly chosen from the group of cellulosic derivatives (hydroxypropylcellulose), povidone (polyvinylpyrrolidone), sucrose, gums, starches, gelatin, macrogols, sucroesters and poloxamers.

According to one embodiment, use is in particular made of hydrophilic polymers, preferably PEG or PVP in an aqueous solution in a proportion of from approximately 10% to 45% by weight in the aqueous solution.

Preferably, when the binder is a hydrophilic polymer, the percentage by weight of the binder is less than 10% by weight, preferably less than 5% by weight, preferably ranging from 1% to 5% by weight, relative to the weight of the composition of the coated granule.

According to another embodiment, use is made of hydrophilic agents chosen from hot-melt agents (melting point < 85°C) such as macrogols (PEG), sucroesters or else poloxamers, in particular when moisture-sensitive active ingredients are used. The

concentrations of hot-melt binders used are about from 0.2% to 20%, preferably from 1% to 15% by weight, relative to the amount of active ingredient to be granulated.

Preferably, when the binder is a hot-melt agent, the percentage by weight of the binder is less than 18% by weight, preferably less than 13.5% by weight, relative to the weight of the composition of the coated granule, and preferably from 0.2% to 13.5% by weight, relative to the weight of the composition of the coated granule.

The diluents used in granulation in order to increase the load to be granulated or else in order to facilitate the dissolution of the active ingredient are preferably chosen from polyols, celluloses, sugars, lactoses, starches, kaolin, calcium phosphates, calcium carbonates or magnesium carbonates, or mixtures thereof. These diluents are present in a content of between 0 and 80% of the weight of the granule, which represents 0 to 39% by weight of the weight of the composition of the coated granule.

The lubricants used in granulation in order to improve the fluidization are preferably chosen from silicas and talc. These lubricants are present in a content of between 0 and 2% of the weight of the granule, which represents 0 to 1.8% by weight of the weight of the composition of the coated granule.

### **3. Characteristics of the granular active ingredient**

The granule comprising the active ingredient and the binder, obtained at the end of the first granulation step, has a particle size of less than 500  $\mu\text{m}$ , preferably on average less than 200  $\mu\text{m}$ .

### **4. Fatty matrix**

The fatty matrices are chosen from the group of saturated fatty acids with long C14 to C18, preferably C16 to C18, carbon-based chains, pure or as mixtures, and/or their corresponding fatty alcohols and/or the corresponding esters of fatty acids and alcohols. Preferably, the fatty matrix consists of stearic acid, palmitic acid, myristic acid, pure or as mixtures, and/or their corresponding fatty alcohols. More preferentially, the fatty matrix consists only of stearic acid, which is a C18 saturated fatty acid.

Preferably, the fatty matrix represents more than 50% by weight of the composition and up to 85% by weight of the composition; more preferentially from 51% to 65% by weight of the composition of the coated granule.

According to one preferred embodiment, use is made, as fatty matrix, of stearic acid in a proportion of more than 50% by weight, relative to the weight of the composition of the coated granule, preferably from 51% to 65% in order to improve the masking of the taste of very unpleasant molecules.

## 5. Fatty matrix adjuvants

The adjuvants are chosen from the group of surfactants such as phospholipids, polysorbate or lauryl sulphate, hydrophilic excipients such as sucrose, polyols, cellulose, lactose, silica, dicalcium phosphate, starch, povidones or macrogols, and agents which are soluble at acidic pH, such as methacrylic derivatives; preferably, phospholipids are used. Preferably, the adjuvant used is a glycerolipid, in particular a phospholipid. More preferentially, this phospholipid is a lecithin (phosphatidylcholine), preferably soybean lecithin.

Preferably, the percentage by weight of the adjuvant added to the fat in the coating step is less than 10% by weight, preferably less than 5% by weight, preferably ranging from 0.5% to 3.5% or else from 1% to 3% by weight, relative to the weight of the composition of the coated granule.

According to one preferred embodiment, phospholipids are used as adjuvant, preferentially soybean lecithin, in a proportion of from 1% to 3% by weight, relative to the weight of the composition of the coated granule, in order to improve the dissolution profile.

### **Characteristics of the composition of medicinal active ingredient:**

#### **Particle size**

The particle sizes of the products resulting from this method are about a few hundred microns (according to the parameters applied and the type of equipment used).

The particle size distribution of the product obtained is distributed according to the following range:

- less than 15% by weight of the coated granules are greater than 500  $\mu\text{m}$ ;
- more than 80% by weight, preferably more than 90% by weight, of the coated granules are between 355 and 90  $\mu\text{m}$ ; and
- less than 20% by weight, preferably less than 5% by weight, of the coated granules are less than 90  $\mu\text{m}$ .

#### **Preferred amounts and ratio**

The composition according to the invention consists of medicinal active ingredient comprising (a) a granular centre consisting of grains of active ingredient agglomerated in the presence of binder, and (b) a layer of coating of said granular centre consisting of fatty matrix.

In this composition, the preferred amounts and ratios of the various combinations of ingredients are represented below:

- 5       • the active ingredient represents a minimum of 30% by weight relative to the weight of the composition of the coated granule; the active ingredient represents a maximum of 48%, preferably a maximum of 40%, the active ingredient preferably represents from 30% to 40%, relative to the weight of the composition of the coated granule;
- 10       • the fatty matrix represents more than 50% and up to 85% by weight of the composition of the coated granule, preferably from 51% to 65%, the fatty matrix optionally comprising an adjuvant, preferably chosen from hydrophilic agents, surfactants or mixtures thereof, and the latter representing less than 10% by weight of the composition, preferably from 1% to 3% by weight, relative to the weight of the composition of the coated granule;
- 15       • the adjuvant, when it is present in the fatty matrix, represents less than 10% by weight of the composition, preferably from 1% to 3% by weight, relative to the weight of the composition of the coated granule;
- 20       • the binder, preferably a hydrophilic polymer or a hot-melt agent, represents less than 18% (for a hot-melt agent) or else less than 10% (for a polymer) by weight, relative to the weight of the composition of the coated granule;
- the diluent, if necessary, as filler, represents a content of from 0 to 39% by weight, relative to the weight of the composition of the coated granule;
- the lubricant, if necessary as flow agent, represents a content of from 0 to 1.8% by weight, relative to the weight of the composition of the coated granule.

### Properties

25       The formulation of the coated granule according to the invention allows effective masking of the taste and of the odours of active ingredients with unpleasant organoleptic properties. This is because the coating of the active ingredient allows the creation of a barrier around said active ingredient so as to mask its taste, its odour and, potentially, its colour.

30       In parallel, products having a relatively prompt release of the active ingredient in vitro are obtained (for example a minimum release of 70% in 60 min).

      Moreover, by virtue of the effective taste masking, it is possible to obtain products with a high dose of active ingredient, for instance containing more than 30% of active ingredient, which makes it possible to notably reduce the doses of products to be administered to the patient, in particular to young children or to the elderly.

According to another advantage, this method makes it possible to combine a high dosage of the active ingredient with heat-sensitive or moisture-sensitive active ingredients.

In addition, it is observed that the physical appearance of the final products obtained remains stable during heat-stability tests (30°C/65%RH).

Furthermore, it is observed that the composition of the coated granule exhibits good stability with respect to moisture.

According to another additional advantage, this method makes it possible, by virtue of the quality of its coating, to inhibit the anaesthetic, irritant, astringent and unpleasant effect in the mouth of certain active molecules.

#### Evaluation of the taste masking:

The taste masking produced by this coating can be evaluated:

- qualitatively, by means of tasting tests carried out by volunteers;
- quantitatively, using analytical methods such as the "glass of water test" in which the amount of active ingredient released at a given time is assayed and a comparison is made with a given bitterness threshold.

The method of the glass of water test, making it possible to replace the tasting test, is described below for the example of pristinamycin:

Medium	demineralized water + 0.2% SDS
Volume	50 ml
Concentration of active ingredient	10000 mg/l
Stirring	50 rpm
Temperature	ambient
Samples	at 5, 10 and 15 minutes
Filtration	double filtration through 0.45 µm + 0.22 µm Millipore
Detection	range 240-270 nm
Cuvette	0.1 cm
Measurement	without dilution

#### Calculation of the concentration in the glass of water:

The concentration of pristinamycin dissolved at time "t" ( $C_{\text{granule}}$ ) is calculated according to the measurement of absorbance at 252 nm in the glass of water  $A_{\text{granule}}$  and of the pristinamycin control ( $A_{\text{pyo control}}$ ) at the concentration  $C_{\text{control}}$  :

$$C_{\text{granule}} \text{ (mg/L)} = (A_{\text{granule}} \times C_{\text{control}}) / A_{\text{pyo control}}$$

The bitterness threshold for pristinamycin is set at **400 mg/L** released in 15 minutes.

In vitro dissolution/release:

The dissolution profiles for the composition obtained at the end of the method are  
5 determined according to the method of the European Pharmacopoeia 2.9.3.

Physical stability

The appearance of the product after 3 months at 30°C and 65%RH is examined.

When the product is nonagglomerated, the result is denoted satisfactory (++) or  
when the product is agglomerated, the result is denoted unsatisfactory (- -).

10 Moisture-stability

The appearance of the granule coated in accordance with the method according to  
the invention is examined when said granule is placed under accelerated degradation  
conditions, i.e. in a controlled chamber at 40°C and 75% relative humidity (RH).

The stability of the active agent is measured by assaying the degradation impurities  
15 produced from said active agent.

The behaviour with respect to moisture, of the product resulting from the method of  
the invention, is compared at various coating contents.

Anaesthetic effect test:

A taste test is carried out by volunteers. The test tablets are broken in half and then  
20 placed in the mouth. The anaesthetic effect in the oral cavity is assessed after several  
minutes following administration of the half-tablet.

When the anaesthetic effect is no longer felt, the result is denoted satisfactory (++)  
or when the anaesthetic effect persists, the result is denoted unsatisfactory (- -).

The molecules which have an anaesthetic effect and which are exemplified in the  
25 compositions tested are drotaverine and riluzole.

Formulation of the external phase

The granule coated with fatty matrix, obtained according to the method of the  
invention, may subsequently be integrated into an external formulation for the  
manufacture of an oral form, such as granules for a sachet, granules for suspension,  
30 tablets to be chewed, tablets to be sucked, tablets to be swallowed or else orodispersible  
tablets or granules.

In the case of the formulation of sachets, the formulation of the external phase can  
be enriched with surfactants or wetting agents in order to improve the resuspension of the  
granules obtained in an aqueous medium.

Other excipients, such as fillers or diluents, colourants, sweeteners, viscosity modifiers or gelling agents, adsorbents, buffers or flavourings may also be added to the formulation for the purpose of improving the final appearance of the product.

5        **Examples**

The following examples illustrate the present invention without, however, limiting the scope thereof.

10       **A. Preparation of the granular medicinal active ingredients coated with a fatty matrix**

Various active ingredients characterized by their strong unpleasant odour and/or their very pronounced bitterness or else having an anaesthetic, hot, irritant or astringent effect were used in the tests.

15       **1. Description of the hot melt method for obtaining the compositions according to the invention**

Three kilos of pristinamycin in the crude state are fluidized in a fluidized air bed.

Over the course of a few minutes of fluidization at an average flow rate of 90 m<sup>3</sup>/h, spraying is initiated at an average flow rate of 30 g/min.

20       The granulation solution is composed of 1.4 kg of water in which 600 g of PEG 6000 fine powder are dispersed, i.e. a concentration of 30% of binder.

The inlet temperature is set at 75°C for a product and outlet temperature equal to 40°C. The spraying lasts approximately 1 hour. The grain obtained is finely granulated and has a particle size predominantly less than 200 µm.

25       In the case of moisture-sensitive active ingredients, the granulation can be carried out directly with PEG 6000 alone in the molten state.

The fatty matrix consisting of stearic acid is melted at 80°C. After homogenization of the fatty substance, the phospholipid adjuvant, in an amount of from 2% to 5% according to the formulations, is added to the molten fatty matrix until complete homogenization of the mass is obtained.

30       Stirring is maintained throughout the duration of spraying.

A few hundred grams of granules are fluidized in the fluidized air bed with an air flow rate of 70 to 90 m<sup>3</sup>/h (the latter is adjusted according to the progression of the step, i.e. according to the load and the density gradually acquired by the grain).

35       The inlet air temperature during the coating is set between 30° and 40°C. The molten mixture is then sprayed at a flow rate of 15 g/min on average.

Once set, this flow rate remains constant throughout the duration of the spraying. The spray pressures used are themselves also kept constant and are between 0.5 and 0.9 bar. The air used is heated to a target temperature of 90°C.

- The spraying time varies according to the formula. Once the spraying is complete,  
5 the inlet air temperature is cut and the granule is thus cooled before being discharged.

**2. Influence of the fatty matrix and of the adjuvant in a composition of active agent according to the invention on the particle size, the masking of bitterness, the dissolution, the physical stability and the anaesthetic effect of the active ingredient**

10

Tables I and II represent all the formulations tested from C1 to C20.

<b>Table I</b>												
Ingredients	% by weight	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11
Active ingredient	pristinamycin	32.5	34.6	32.8	29	25.1	25.2	24.7	25	18.3	20.8	23.4
Lubricant	aerosil 200	0.3	0.4	0.3	0.3	0.3	0.3	0.3				
Binder	PEG 600	6.6	7	6.6	5.9	5.1	5.1	5	5	3.7	4.2	4.7
Fatty matrix	stearic acid		60		64.8	64.5	64.4	65	65	75	73	70
	stearyl alcohol			60.3								
	palmitic acid	60.6										
Adjuvant	phospholipid					5			2	3	2	2
	polysorbate							5				
	PEG 6000						5					
<b>Results</b>												
Particle size profile		++	++	++	++	++	--	++	++	++	++	++
Bitterness masking		++	++	++	++	++	++	--	++	++	++	++
Dissolution profile T0		--	++	++	--	++	--	--	++	++	++	++
Physical stability T 3 months 40°C/75%RH		++	++	++	/	/	/	/	++	/	/	/
Dissolution profile T 3 months 30°C/65%RH		--	++	--	/	/	/	/	/	/	/	/

<b>Table II</b>										
Ingredients	% by weight	C12	C13	C14	C15	C16	C17	C18	C19	C20
Active ingredient	drotaverine	30	29.5	28						
	clobazam				18	14	16			
	riluzole							43		
	clopidogrel									32.3
	ketoprofen								35	
Diluent	mannitol				25	19.5	22.3			
Lubricant	colloidal silica							0.9		
Binder	PVP	4	4.5	4	2	1.5	1.7	5.1	1.85	
	PEG									5.7
Fatty matrix	stearic acid	65	65	65	55	65	59	51	60	60
Adjuvant	phospholipid		1	3			1		2	2
Results										
Particle size profile		++	++	++	++	++	++	++	++	
Taste masking		++	++	++	++	++	+	++	++	
Anaesthetic effect inhibition		++	++	++	N	N	N	++	N	N
Dissolution profile T0		--	-	++	/	++	/	++	++	
++: Satisfactory result    --: Unsatisfactory result    /: Absence of result N: Not concerned										

## **Conclusions**

### **1) Presence of the adjuvant:**

5            It may be noted that the addition of an adjuvant to the formulation in the fatty matrix, of phospholipid type added in an amount of a few percent, 2 to 5%, makes it possible to accelerate dissolution.

### **2) Choice of fatty substance:**

10           It may be noted that, according to the type of fatty substance, for the same masking quality, the dissolution profiles and the physical heat-stability are not equivalent (cf. Examples C1, C2, C3). The best compromise is obtained with stearic acid, which is a C18 saturated fatty acid.

15           **3) Choice of adjuvant:**

The comparison of several types of adjuvants showed that phospholipid makes it possible to obtain the best bitterness masking/dissolution compromise (cf. Examples C5 to C11). The preferred phospholipid is soybean lecithin.

#### 5           **4) Choice of adjuvant content:**

When a phospholipid content of more than 10% is used in the coating formula, a technical difficulty is observed and the method cannot be carried out.

When a phospholipid content of less than 5% is used in the coating formula, it is observed that the method can be carried out, but that a composition agglomeration  
10   phenomenon may occur during storage.

Few differences are noted between the percentages of 1, 2 and 3% (cf. Examples C13, C14, C17 and C19).

### 15           **3. Effect of a composition of active ingredient according to the invention on the stability of said active agent with respect to moisture**

Nicorandil (N-(2-hydroxyethyl)nicotinamide nitrate) was chosen as an example of an active molecule particularly sensitive to moisture.

It was used according to the method of the invention with, in step E1), granulation using a hot-melt agent, polyethylene glycol 6000 or PEG 6000. This granule obtained is  
20   then coated according to step E2) of the method according to the invention at various coating contents with respect to stearic acid: 30% (comparative example), then 54% and 80% (according to the invention). Step E3) is carried out for all the batches.

The resulting coated granules are then placed under stressing temperature and humidity conditions at 40°C/75%RH in a climatic chamber under open conditions (open  
25   pillbox).

After 3 days, nicorandil impurity assay analyses are performed by HPLC.

The formulae of the compositions tested, corresponding to the various coating contents, are the following (the percentages are expressed by weight relative to the composition of the coated granule):

30

	Components	Percentage composition (%)
<b>COMPOSITION A</b>	nicorandil	59.50
	PEG 6000	10.50
	stearic acid	30.00
<b>COMPOSITION B</b>	nicorandil	38.93

	PEG 6000	6.87
	stearic acid	54.20
<b>COMPOSITION C</b>	nicorandil	17.00
	PEG 6000	3.00
	stearic acid	80.00

The results of the nicorandil degradation impurity assay analyses are given in the table below:

	<b>COMPOSITION A</b>	<b>COMPOSITION B</b>	<b>COMPOSITION C</b>
<b>Sum impurities (%)</b>	14.61	12.63	9.14
SG100* (%)	10.34	8.97	7.47
Ethyl nicotinamide polymer * (%)	2.82	2.39	0.56

5 \* : known major impurities of nicorandil

These results demonstrate that the coating containing stearic acid significantly improves the stability of nicorandil placed under very high relative humidity conditions. The percentage of major impurities is significantly reduced on compositions B (54% stearic acid) and C (80% stearic acid) compared with composition A (30% stearic acid).

These results show the protective effect, with respect to moisture, of a coating containing stearic acid at greater than 50% in the composition of the coated granule.

#### 15 **4. Effect of a composition of active ingredient according to the invention on the inhibition of the anaesthetic effect of said active agent**

Drotaverine was chosen as an example of an active molecule having a persistent anaesthetic effect.

It was used according to the method of the invention with, in step E1), a povidone (PVP-K30)-based aqueous-phase granulation.

20 The resulting granular centre is then coated, in step E2), with stearic acid at various coating contents. Step E3) is finally carried out.

The composition of the coated granule comprises approximately 43% of drotaverine, from 1% to 10% of povidone and various corresponding stearic acid contents.

The introduction of an external phase into the composition of the coated granule thus obtained allows tableting.

The tablets are tasted by volunteers.

The study made it possible to demonstrate that a coating content of less than or  
5 equal to 50% was not sufficient to suitably mask the anaesthetic effect of drotaverine. On the other hand, when the coating content is greater than 50%, and preferably about 65% by weight of the composition of the coated granule, the anaesthetic effect of drotaverine is greatly reduced, or even nonexistent.

## 10 **5. Pharmaceutical compositions according to the invention**

The percentages indicated below are expressed by total weight of the composition:

### **a) Preparation of granules or of a powder to be swallowed, in sachets:**

The formulation of the external phase is the following:

- 15 - Diluents: from 5% to 90%
- Lubricants: from 0.5% to 2%
- Viscosity modifiers : from 1% to 10%
- Effervescent agents: from 1% to 7%
- Sweeteners: from 0.5% to 5%
- 20 - Flavours: from 1% to 5%
- Colourants: from 0.1% to 3%
- Buffering agents: from 0.1% to 3%
- Sequestering agents: from 0.1% to 10%.

The external phase is added to the coated granules produced according to the  
25 invention in a proportion of from 40% to 70%.

All of the excipients of the external phase, with the exception of the lubricants, are mixed with the coated granules. A lubrication step is then carried out before the placing in sachets.

### 30 **b) Preparation of tablets to be chewed, swallowed or sucked:**

The formulation of the external phase is the following:

- Diluents: from 5% to 90%
- Lubricants: from 0.5% to 5%
- Sweeteners: from 0.5% to 5%
- 35 - Flavours: from 1% to 5%
- Colourants: from 0.1% to 3%.

The external phase is added to the coated granules produced according to the invention in a proportion of from 40% to 70%.

All of the excipients of the external phase, with the exception of the lubricants, are mixed with the coated granules. A lubrication step is then carried out and the whole is then tableted.

**c) Preparation of orodispersible or dispersible tablets:**

The formulation of the external phase is the following:

- Diluents: from 5% to 90%
- Disintegrating agents: from 0 to 30%
- Salivating agents: from 1% to 5%
- Lubricants or flow agents: from 0.5% to 5%
- Sweeteners: from 0.5% to 5%
- Flavours: from 1% to 5%
- Colourants: from 0.1% to 3%.

The external phase is added to the coated granules produced according to the invention in a proportion of from 40% to 70%.

All of the excipients of the external phase, with the exception of the lubricants, are mixed with coated granules. A lubrication step is then carried out and the whole is then tableted.

**d) Orodispersible ketoprofen tablets (25 mg):**

Coated granule according to the invention:

- Ketoprofen: 7.81%
- Binder: 0.41%
- Stearic acid: 8.60%

External phase:

- Disintegrating agent: 7%
- Diluents: 73.58%
- Lubricants or flow agents: 1%
- Flavours and sweeteners: 1.6%.

All of the excipients of the external phase, with the exception of the lubricants, are mixed with the coated granules. A lubrication step is then carried out and the whole is then tableted.

**CLAIMS**

1. Method for preparing a composition of medicinal active ingredient comprising  
(a) a granular centre consisting of grains of active ingredient, agglomerated in the  
presence of binder, and (b) a layer of coating of said granular centre consisting of  
5 fatty matrix, in which composition:

- the active ingredient represents a minimum of 10%, preferably 20% or else  
30% by weight, relative to the weight of the composition of the coated granule;  
the active ingredient represents a maximum of 48%, preferably a maximum of  
40%, the active ingredient preferably represents from 20% to less than 40%,  
10 relative to the weight of the composition of the coated granule, more  
preferentially the active ingredient represents from 30% to 40%, relative to the  
weight of the composition of the coated granule;
- the fatty matrix represents more than 50% and up to 85% by weight of the  
composition of the coated granule, preferably from 51% to 65%, the fatty  
15 matrix optionally comprising an adjuvant, preferably chosen from hydrophilic  
agents, surfactants or mixtures thereof, and the latter representing less than  
10%, preferably from 1% to 3% by weight, relative to the weight of the  
composition of the coated granule;
- the binder, preferably a hydrophilic agent chosen from hydrophilic polymers or  
20 hot-melt agents, represents from 0.2% to 18% by weight, relative to the weight  
of the composition of the coated granule, preferably the binder represents less  
than 18% by weight for a hot-melt agent or else preferably the binder  
represents less than 10% by weight for a hydrophilic polymer;
- the diluent, if necessary, as filler, represents a content of 0 to 39%, relative to  
25 the weight of the composition of the coated granule;
- the lubricant, if necessary, as flow agent, represents a content of 0 to 1.8%,  
relative to the weight of the composition of the coated granule;

the method comprising the steps of:

- E1) preparing the granular centre by spraying an aqueous solution comprising  
30 the binder or by spraying the binder in the molten state onto the active  
ingredient alone or as a mixture with a diluent and/or a lubricant;
- E2) coating by spraying, onto the granules, said fatty matrix pre-melted in a  
melting kettle at a temperature approximately 10 to 20°C above its melting  
point;
- 35 E3) cooling the composition obtained.

2. Method for preparing a composition according to Claim 2, in which:
- the active ingredient represents a minimum of 10% and a maximum of 48%, preferably from 20% to less than 40% by weight of the composition of the coated granule, and
  - 5 • the fatty matrix comprising an adjuvant represents more than 50% by weight and up to 85% by weight of the composition of the coated granule.
3. Method for preparing a composition according to Claim 2, in which:
- the active ingredient represents from 30% to 40%, relative to the weight of the composition of the coated granule, and
  - 10 • the fatty matrix represents from 51% up to 65% by weight of the composition of the coated granule.
4. Method according to one of Claims 1 to 3, in which the size of the coated granules obtained at the end of step E3) is less than 500  $\mu\text{m}$ , preferably less than 355  $\mu\text{m}$ , preferably ranging from 100 to 300  $\mu\text{m}$ .
5. Method according to one of Claims 1 to 4, in which the particle size of the final product obtained at the end of step E3) is distributed according to the following range:
- 20 • less than 15% by weight of the coated granules are greater than 500  $\mu\text{m}$ ;
  - more than 80% by weight, preferably more than 90% by weight, of the coated granules are between 355 and 90  $\mu\text{m}$ ; and
  - 25 • less than 20% by weight, preferably less than 5% by weight, of the coated granules are less than 90  $\mu\text{m}$ .
6. Method according to one of Claims 1 to 5, in which the aqueous solution used in step E1 comprises, as binder, a hydrophilic polymer preferably chosen from the group of cellulosic derivatives (hydroxypropylcellulose), povidone (polyvinylpyrrolidone), sucrose, gums, starches, gelatin and macrogols (polyethylene glycols), which represents approximately from 15% to 45%, preferably from 20% to 40% by weight of said aqueous solution.
7. Method according to one of Claims 1 to 6, in which the binder used in step E1 for the granulation is a hot-melt agent chosen from macrogols (PEGs), sucroesters or else poloxamers, and represents approximately from 0.2% to 20%, preferably

from 1% to 15% by weight, relative to the amount of active ingredient to be granulated in step E1).

5       **8.**     Method according to one of Claims 1 to 7, in which the fatty matrix consists of saturated fatty acids with long C14 to C22, preferably C16 to C18, carbon-based chains, pure or as mixtures, and/or their corresponding fatty alcohols.

10       **9.**     Method according to one of Claims 1 to 8, in which the fatty matrix consists of stearic acid, palmitic acid, myristic acid, pure or as mixtures, and/or their corresponding fatty alcohols.

**10.**    Method according to Claim 9, in which the fatty matrix consists of stearic acid.

15       **11.**   Method according to one of Claims 1 to 10, in which the fatty matrix comprises an adjuvant chosen from the group of surfactants (phospholipid, polysorbate, lauryl sulphate), hydrophilic excipients such as sucrose, polyols, cellulose, lactose, silica, dicalcium phosphate, carbonates, starch, macrogols and agents which are soluble at acidic pH (methacrylic derivatives), pure or as mixtures.

20       **12.**   Method according to Claim 11, in which the adjuvant as a mixture with the fatty matrix is soybean lecithin.

25       **13.**   Method according to one of Claims 1 to 8, in which said fatty matrix coating the granular centre consists of stearic acid and in which said fatty matrix comprises soybean lecithin as adjuvant.

30       **14.**   Method according to one of Claims 1 to 13, in which the percentage by weight of the adjuvant added to the fat in step E2 is less than 10% by weight, preferably less than 5% by weight, preferably ranging from 1% to 3% by weight, relative to the weight of the final composition.

35       **15.**   Method according to one of Claims 1 to 14, in which the percentage by weight of the binder constituting the coating of the granule obtained in step E1 represents from 1% to 5% by weight, relative to the weight of the final composition, for a hydrophilic polymer and from 0.2% to 18% for a hot-melt agent.

16. Method according to one of Claims 1 to 15, in which the active ingredient is chosen from the group consisting of antibiotics such as cephalosporins and macrolides, advantageously chosen from: pristinamycin, cefpodoxime, roxithromycin, spiramycin, rovamycin and levofloxacin, or the group consisting of corticoids such as prednisolone or methylprednisolone, or else the group consisting of NSAIDs such as tiaprofenic acid, ketoprofen, ketoprofen lysinate or ibuprofen, or the group consisting of analgesics such as paracetamol, or else the group consisting of zopiclone, riluzole, zolpidem, clobazam, thiocolchicoside, drotaverine hydrochloride or base, amodiaquine hydrochloride, diltiazem, levocetirizin, mizolastine, dronedarone, celivarone, dramamine, ramipril, irbesartan, clopidogrel, leflunomide, nicorandil, lysine acetyl salicylate, magnesium citrate, levothyroxine, sodium valproate, rifampicin, artesunate and omeprazole.
17. Method according to one of Claims 1 to 16, followed by a step E4 of formulating the coated granules obtained in step E3 with excipients such as diluents, fillers, viscosity modifiers, disintegrating agents, effervescent agents, colourants, sweeteners, salivating agents, flavourings, buffers and sequestering agents, flow agents and lubricants for the manufacture of an oral formulation in the form of granules for sachets, granules for oral suspension, or granules for conventional tablets or for orodispersible tablets.
18. Composition of medicinal active ingredient which can be obtained according to the method described in one of Claims 1 to 17.
19. Pharmaceutical composition comprising the composition of medicinal active ingredient as defined in Claim 18 or prepared according to the method of any one of Claims 1 to 17.
20. Composition according to Claim 19, characterized in that it is in the form of sachets for oral suspension; tablets to be chewed, swallowed or sucked; or orodispersible or water-dispersible tablets; or powder to be swallowed.
21. Use of a composition of medicinal active ingredient as defined in Claim 18 or prepared according to the method of any one of Claims 1 to 17, for preparing a pharmaceutical composition in the form of sachets for oral suspension, powders to

be swallowed, tablets to be chewed, tablets to be swallowed, tablets to be sucked, orodispersible tablets or water-dispersible tablets, and having a masked taste.

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/IB2011/051736

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61K9/00 A61K9/16 A61K9/50  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>FAHAM A ET AL: "HOT MELT COATING TECHNOLOGY: INFLUENCE OF COMPRITOL(R) 888 ATO AND GRANULE SIZE ON CHLOROQUINE RELEASE", DIE PHARMAZIE, GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, ESCHBORN, DE, vol. 55, no. 6, 1 June 2000 (2000-06-01), pages 444-448, XP000932193, ISSN: 0031-7144 the whole document</p> <p style="text-align: center;">----- -/--</p>	1-21

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 July 2011

Date of mailing of the international search report

13/07/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Giménez Miralles, J

## INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2011/051736

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOZWIAKOWSKI M J ET AL: "CHARACTERIZATION OF A HOT-MELT FLUID BED COATING PROCESS FOR FINE GRANULES", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US LNKD-DOI:10.1023/A:1015972007342, vol. 7, no. 11, 1 November 1990 (1990-11-01), pages 1119-1126, XP002052859, ISSN: 0724-8741 the whole document	1-21
X	FR 2 753 904 A1 (GATTEFOSSE ETS SA [FR]) 3 April 1998 (1998-04-03) examples	1-21
X	WO 2005/065639 A2 (TORRENT PHARMACEUTICALS LTD [IN]; GUPTA VINOD KUMAR [IN]; VAYA NAVIN []) 21 July 2005 (2005-07-21) examples	1-21
X	FR 2 857 263 A1 (SANOFI SYNTHELABO [FR]) 14 January 2005 (2005-01-14) examples	1-21
X	EP 1 479 383 A1 (ETHYPHARM SA [FR]; TORAY [JP] ETHYPHARM SA [FR]; TORAY INDUSTRIES [JP]) 24 November 2004 (2004-11-24) paragraphs [0031], [0032], [0037], [0039]	1-21
X	US 4 948 622 A (KOKUBO HIROYASU [JP] ET AL) 14 August 1990 (1990-08-14) examples	1-21
X	US 5 296 236 A (SANTUS GIANCARLO [IT] ET AL) 22 March 1994 (1994-03-22) examples	1-21
X	WO 97/18798 A1 (RECORDATI CHEM PHARM [CH]) 29 May 1997 (1997-05-29) examples	1-21
X	US 5 891 476 A (REO JOE P [US] ET AL) 6 April 1999 (1999-04-06) examples	18-21
A	WO 02/07706 A1 (GATTEFOSSE ETS SA [FR]; BENAMEUR HASSAN [FR]; BARTHELEMY PHILIPPE [FR]) 31 January 2002 (2002-01-31) examples	1-21

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2011/051736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2753904	A1	03-04-1998	AU 4464897 A 24-04-1998
			DE 69713367 D1 18-07-2002
			DE 69713367 T2 06-03-2003
			EP 0935459 A1 18-08-1999
			ES 2176785 T3 01-12-2002
			WO 9814176 A1 09-04-1998
			JP 2001501218 A 30-01-2001
			KR 20000048761 A 25-07-2000
			US 6194005 B1 27-02-2001
-----	-----	-----	-----
WO 2005065639	A2	21-07-2005	NONE
-----	-----	-----	-----
FR 2857263	A1	14-01-2005	AU 2004255504 A1 20-01-2005
			BR PI0412364 A 05-09-2006
			CA 2529461 A1 20-01-2005
			CN 1842331 A 04-10-2006
			EP 1646379 A2 19-04-2006
			WO 2005004860 A2 20-01-2005
			JP 2007516188 A 21-06-2007
			KR 20060032628 A 17-04-2006
			MX PA06000332 A 30-03-2006
			US 2006153925 A1 13-07-2006
			ZA 200600159 A 28-03-2007
-----	-----	-----	-----
EP 1479383	A1	24-11-2004	AT 341312 T 15-10-2006
			CA 2525542 A1 02-12-2004
			CN 1791390 A 21-06-2006
			DE 60308828 T2 24-05-2007
			ES 2272914 T3 01-05-2007
			WO 2004103350 A1 02-12-2004
			JP 2006528969 A 28-12-2006
			US 2007269506 A1 22-11-2007
-----	-----	-----	-----
US 4948622	A	14-08-1990	EP 0349644 A1 10-01-1990
			WO 8905635 A1 29-06-1989
			JP 1165530 A 29-06-1989
			JP 2063846 C 24-06-1996
			JP 7100665 B 01-11-1995
-----	-----	-----	-----
US 5296236	A	22-03-1994	NONE
-----	-----	-----	-----
WO 9718798	A1	29-05-1997	AT 221372 T 15-08-2002
			AU 7694896 A 11-06-1997
			DE 69622739 D1 05-09-2002
			EP 0862421 A1 09-09-1998
			IT MI952427 A1 22-05-1997
-----	-----	-----	-----
WO 9718798	A1		JP 2000500477 A 18-01-2000
-----	-----	-----	-----
US 5891476	A	06-04-1999	NONE
-----	-----	-----	-----
WO 0207706	A1	31-01-2002	AT 262320 T 15-04-2004
			AU 7854601 A 05-02-2002
			DE 60102472 D1 29-04-2004
			DE 60102472 T2 20-01-2005
			EP 1301176 A1 16-04-2003
			FR 2811912 A1 25-01-2002
			JP 2004504339 A 12-02-2004

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

International application No

PCT/IB2011/051736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2003170312 A1	11-09-2003
-----			